If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
GIP/GLP incretin blend · weight-management research
Overview
This research preparation combines Retatrutide (LY3437943, a triple GLP-1/GIP/glucagon receptor agonist) and Tirzepatide (LY3298176, a dual GIP/GLP-1 receptor agonist) in a single vial at a fixed 20 mg + 40 mg ratio. Both are incretin-mimetic peptides with independent Phase 3 clinical data for their individual effects; the fixed combination itself has not been evaluated in a dedicated clinical trial and is supplied for research use only. Vialdyne co-formulates Retatrutide + Tirzepatide (Blend) to the stated ratio and releases it with a batch-specific Certificate of Analysis reporting per-component MS identity and RP-HPLC purity; fill accuracy is available on request and listed on the COA when tested. The component breakdown is documented on the lot COA.
Applications & buyer fit
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Ratio target, the analytical method to verify it, stability protocol, and packaging are defined in the OEM brief before the first commercial run.
Primary buyer fit: academic and contract research laboratories.
Specifications
Batch COAs and test reports
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COARetatrutide 20mg+Tirzepatide 40mg 20 mg + 40 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Independent test fails? Full refund. How it works
Browse all COAs and reportsRegulatory note
Research-use-only reference material; not for human or veterinary use.
Frequently asked questions
Retatrutide + Tirzepatide (Blend) ships as white lyophilized powder with a batch-specific Certificate of Analysis reporting RP-HPLC purity (See per-component COA), mass-spec identity, and appearance. Recommended storage: -20°C; reconstituted 2–8°C. Supplied strictly as a research reference material — not for human or veterinary use.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Related peptides
GIP / GLP-1 / glucagon tri-agonist
Nasal spray listedCapsules listed
GIP / GLP-1 dual receptor agonist
Nasal spray listed
Cagrilintide + Semaglutide combination
Nasal spray listed